Equities
  • Price (EUR)27.58
  • Today's Change-0.50 / -1.78%
  • Shares traded2.56k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SCHOTT Pharma AG & Co. KGaA is a Germany-based Company, which designs advanced drug containment and drug delivery solutions for the pharmaceutical and biotech industries. The Company's product portfolio ranges from drug containment solutions to drug delivery systems manufactured in collaboration with industry partners. Its selection of pharmaceutical syringes, cartridges, vials, and ampoules is one of the widest and advanced on the market for injectable drugs.

  • Revenue in EUR (TTM)905.64m
  • Net income in EUR158.11m
  • Incorporated2022
  • Employees4.65k
More ▼

Institutional shareholders

9.41%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Mar 20244.40m2.92%
T. Rowe Price International Ltd.as of 31 Mar 20242.50m1.66%
DWS Investment GmbHas of 30 Apr 20241.76m1.17%
Threadneedle Asset Management Ltd.as of 30 Apr 20241.27m0.85%
The Vanguard Group, Inc.as of 30 Apr 20241.27m0.84%
Union Investment Privatfonds GmbHas of 30 Sep 2023892.10k0.59%
Lazard Asset Management Ltd.as of 30 Apr 2024877.43k0.58%
Deka Investment GmbHas of 31 Dec 2023604.60k0.40%
ClearBridge Investments LLCas of 31 Mar 2024310.70k0.21%
BlackRock Fund Advisorsas of 09 May 2024293.97k0.20%
More ▼
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.